Apogee Therapeutics, Inc.
General ticker "APGE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.9B (TTM average)
Apogee Therapeutics, Inc. follows the US Stock Market performance with the rate: 47.0%.
Estimated limits based on current volatility of 0.4%: low 133.11$, high 134.05$
Factors to consider:
- Earnings expected soon, date: 2026-08-10 bmo
- Total employees count: 261 (+33.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: No approved products, Clinical trial failure, Capital raising, Regulatory and compliance, Market competition
- Current price 31.1% above estimated high
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [44.43$, 102.25$]
- 2026-12-31 to 2027-12-31 estimated range: [28.88$, 71.43$]
Financial Metrics affecting the APGE estimates:
- Negative: with PPE of -18.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.87 <= 0.30
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.44 < Investing cash flow per share per price, % of -3.85
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 96.45 > 63.79
Short-term APGE quotes
Long-term APGE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $93.00MM | $216.87MM | $285.60MM |
| Operating Income | $-93.00MM | $-216.87MM | $-285.60MM |
| Non-Operating Income | $9.02MM | $34.74MM | $30.03MM |
| R&D Expense | $68.42MM | $167.87MM | $214.71MM |
| Income(Loss) | $-83.98MM | $-182.13MM | $-255.56MM |
| Taxes | $0.00MM | $0.02MM | $0.28MM |
| Net Income(Loss)* | $-83.98MM | $-182.15MM | $-255.84MM |
| Stockholders Equity | $379.91MM | $716.79MM | $903.88MM |
| Assets | $401.40MM | $753.95MM | $937.13MM |
| Operating Cash Flow | $-74.76MM | $-171.17MM | $-227.45MM |
| Capital expenditure | $0.17MM | $1.15MM | $5.15MM |
| Investing Cash Flow | $-273.91MM | $-300.46MM | $-179.57MM |
| Financing Cash Flow | $315.39MM | $495.11MM | $396.49MM |
| Earnings Per Share** | $-1.66 | $-3.30 | $-4.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.